Biotech
Nura Bio
Nura Bio raises $68M Series A at $300M valuation
$68M
Total Raised
Series A
Latest Round
2021
Founded
70+
Employees
South San Francisco, CA
1 min read
Quick Facts
Valuation
$300M
Latest Round Size
$68M
Latest Round Date
October 2024
Nura Bio: Series A Funding Round
Nura Bio has successfully raised $68M in Series A funding, reaching a valuation of $300M.
Company Overview
Biopharmaceutical company developing therapies for neurological diseases
Funding Details
The Series A round was led by Atlas Venture, with participation from Deerfield Management.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2021
- Employees: 70+
- Category: Biotech
Investment
Nura Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Atlas Venture: Verified investor in Series A
- Deerfield Management: Verified investor in Series A
Key Investors
Atlas Venture
Lead Investor
Verified investor in Series A
Deerfield Management
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M